Instead, FDA-approved avapritinib (Ayvakit), another PDGFRα inhibitor, was investigated in clinical trials to treat patients with gastrointestinal stromal tumors (GISTs) presenting a PDGFRA D842V mutation, demonstrating a high response rate in 85% of patients. Here, PDGFRA is linked to gastrointestinal stromal tumor.